Orchid Biomedical Systems Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 34 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -2.90%
(FY 2022)
- Profit 5.46%
(FY 2022)
- Ebitda -35.00%
(FY 2022)
- Net Worth 5.21%
(FY 2022)
- Total Assets -25.16%
(FY 2022)
About Orchid Biomedical Systems
The Corporate was formerly known as Tulip Marketing Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Deepak Tripathi, Alok Kumar, and Narendra Makkar serve as directors at the Company.
- CIN/LLPIN
U52311MH1990PTC055671
- Company No.
055671
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 1990
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Orchid Biomedical Systems?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Tripathi  | Director | 02-Feb-2024 | Current |
| Alok Kumar | Director | 31-Jan-2017 | Current |
Narendra Makkar  | Director | 16-Jun-2023 | Current |
Financial Performance and Corporate Structure Insights of Orchid Biomedical Systems.
Orchid Biomedical Systems Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 2.9% decrease. The company also saw a slight improvement in profitability, with a 5.46% increase in profit. The company's net worth moved up by a moderate rise of 5.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orchid Biomedical Systems?
In 2020, Orchid Biomedical Systems had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biosense Technologies Private LimitedActive 16 years 15 daysDeepak Tripathi, Alok Kumar and 1 more are mutual person
Tulip Diagnostics Private LimitedActive 36 years 6 daysDeepak Tripathi, Alok Kumar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orchid Biomedical Systems?
Orchid Biomedical Systems has a workforce of 6 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orchid Biomedical Systems, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orchid Biomedical Systems's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
